Health secretary Wes Streeting is considering expanding the existing schedule to age groups beyond infants, such as teenagers.
At Advanced Therapies, investors noted that early planning, adaptability and building trust will help a biotech startup succeed.
During the review process, the FDA provided label drafts in December 2025 and March 2026.
Sanofi’s agent uses mRNA that produces transient CAR-T cells, allowing repeated dosing.
R1 plans to initiate a Phase IIb study of AP306 later this year.
The court ruling reverses several changes by the CDC’s vaccine panel to childhood immunisation recommendations.
